Market Place
Sourcing Support
Benitec Bio Unveils High And Low Dose BB-301 Phase 1B/2A Results
28 Apr 2026 //
GLOBENEWSWIRE
MDA Accepts Benitec`s Late-Breaking BB-301 Abstract
23 Feb 2026 //
GLOBENEWSWIRE
Benitec Bio Unveils Q2 2026 Financials And Operational Update
12 Feb 2026 //
GLOBENEWSWIRE
Benitec Bio Shows Strong, Durable Efficacy In BB-301 Ph 1B/2A
11 Jan 2026 //
GLOBENEWSWIRE
Benitec Biopharma Announces Proposed Public Offering
05 Nov 2025 //
GLOBENEWSWIRE
Benitec Bio To Update Phase 1B/2A Study Of BB-301
02 Nov 2025 //
GLOBENEWSWIRE
Benitec Bio Unveils 2025 Financials, Updates Operations
22 Sep 2025 //
GLOBENEWSWIRE
Benitec Biopharma Shares Operational Updates
09 Jul 2025 //
GLOBENEWSWIRE
Benitec Biopharma Releases Third Quarter 2025 Financial Results
14 May 2025 //
GLOBENEWSWIRE
Benitec Biopharma Prices $30M Stock Offering
25 Mar 2025 //
GLOBENEWSWIRE
Benitec Bio: Positive BB-301 Ph 1b/2a Data To Be Presented
19 Mar 2025 //
GLOBENEWSWIRE
Benitec Biopharma to Participate in Upcoming Conferences in March
26 Feb 2025 //
GLOBENEWSWIRE
Benitec Bio to Participate in Upcoming Conference in Jan & Feb
27 Jan 2025 //
GLOBENEWSWIRE
Benitec Biopharma to Participate in Upcoming Investor Conferences
26 Nov 2024 //
GLOBENEWSWIRE
Benitec Biopharma Releases Q1 2025 Financial Results & Update
14 Nov 2024 //
GLOBENEWSWIRE
Benitec Biopharma CEO to Attend Guggenheim Healthcare Conference
04 Nov 2024 //
GLOBENEWSWIRE
Benitec Biopharma Announces Updated Investor Webcast Information
14 Oct 2024 //
GLOBENEWSWIRE
Benitec Reports Data From BB-301 In Ph 1b/2a Study at Muscle Society
12 Oct 2024 //
GLOBENEWSWIRE
Benitec Biopharma Releases Full Year 2024 Financial Results
26 Sep 2024 //
GLOBENEWSWIRE
Benitec To Present BB-301 Data At World Muscle Society
18 Sep 2024 //
GLOBENEWSWIRE
Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar
17 Sep 2024 //
GLOBENEWSWIRE
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
01 May 2024 //
GLOBENEWSWIRE
Benitec Announces $40M Oversubscribed Private Placement Financing
18 Apr 2024 //
GLOBENEWSWIRE
Benitec Reports Positive Interim BB-301 OPMD Trial Data
18 Apr 2024 //
GLOBENEWSWIRE
Benitec Biopharma to Discuss BB-301 Program on April 18
09 Apr 2024 //
GLOBENEWSWIRE
Benitec Announces First Subject Dosed in Phase 1b/2a Clinical Trial for BB-301
30 Nov 2023 //
GLOBENEWSWIRE
Benitec Biopharma to Participate in a Fireside Chat at Conference
17 Nov 2023 //
GLOBENEWSWIRE
Benitec Biopharma Announces Closing of $30 Million Underwritten Public Offering
11 Aug 2023 //
GLOBENEWSWIRE
Benitec Biopharma Announces Pricing of $30 Million Underwritten Public Offering
08 Aug 2023 //
GLOBENEWSWIRE
Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023
25 Jul 2023 //
GLOBENEWSWIRE
Benitec Biopharma Receives FDA Clearance of the IND for BB-301
26 Jun 2023 //
GLOBENEWSWIRE
Benitec Biopharma Releases Third Quarter 2023 Financial Results
15 May 2023 //
GLOBENEWSWIRE
Benitec Biopharma to Present at the JMP Securities Life Sciences Conference
08 May 2023 //
GLOBENEWSWIRE
Benitec Biopharma to Present at the OPMD International Conference
08 May 2023 //
GLOBENEWSWIRE
